Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy
Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directe...
Saved in:
Published in | Yonsei medical journal Vol. 58; no. 2; pp. 370 - 379 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Korea (South)
Yonsei University College of Medicine
01.03.2017
연세대학교의과대학 |
Subjects | |
Online Access | Get full text |
ISSN | 0513-5796 1976-2437 1976-2437 |
DOI | 10.3349/ymj.2017.58.2.370 |
Cover
Abstract | Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT).
A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality.
28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001).
PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT. |
---|---|
AbstractList | Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT).PURPOSEPentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT).A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality.MATERIALS AND METHODSA prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality.28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001).RESULTS28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001).PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT.CONCLUSIONPTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT. Purpose: Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limiteddata on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successfulinitial resuscitation through early goal-directed therapy (EGDT). Materials and Methods: A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality. Results: 28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13–19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9–268.6) ng/mL vs. 36.5 (13.7–145.3) ng/mL, p=0.008]. PTX3 had largest AUCROC value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677–0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox’s proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46–15.85, p=0.001). Conclusion: PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT KCI Citation Count: 8 Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3 that can be used to predict mortality in severe sepsis patients who have undergone successful initial resuscitation through early goal-directed therapy (EGDT). A prospective cohort study was conducted among 83 severe sepsis patients with fulfillment of all EGDT components and the achievement of final goal. Plasma PTX3 levels were measured by sandwich ELISA on hospital day (HD) 0, 3, and 7. The data for procalcitonin, C-reactive protein and delta neutrophil index were collected by electric medical record. The primary outcome was 28-day all-cause mortality. 28-day all-cause mortality was 19.3% and the median (interquartile range) APHCH II score of total patients was 16 (13-19). The non-survivors (n=16) had significantly higher PTX3 level at HD 0 [201.4 (56.9-268.6) ng/mL vs. 36.5 (13.7-145.3) ng/mL, p=0.008]. PTX3 had largest AUC(ROC) value for the prediction of mortality among PTX3, procalcitonin, delta neutrophil index, CRP and APACHE II/SOFA sore at HD 0 [0.819, 95% confidence interval (CI) 0.677-0.961, p=0.008]. The most valid cut-off level of PTX3 at HD 0 was 140.28 ng/mL (sensitivity 66.7%, specificity 73.8%). The PTX3 and procalcitonin at HD 0 showed strong correlation (r=0.675, p<0.001). However, PTX3 at HD 0 was the only independent predictive marker in Cox's proportional hazards model (≥140 ng/mL; hazard rate 7.16, 95% CI 2.46-15.85, p=0.001). PTX3 at HD 0 could be a powerful predictive biomarker of 28-day all-cause mortality in severe septic patients who have undergone successful EGDT. |
Author | Song, Young Goo Lee, Kyoung Hwa Jeon, Yong Duk Han, Sang Hoon Choi, Jun Yong Kim, June Myung Kim, Sun Bean Kim, Jung Ho Ann, Hea Won Lee, Ji Un Ku, Nam Su Ahn, Jin Young |
AuthorAffiliation | 1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea 2 Department of Internal Medicine, Infectious Diseases, Hongik Hospital, Seoul, Korea |
AuthorAffiliation_xml | – name: 2 Department of Internal Medicine, Infectious Diseases, Hongik Hospital, Seoul, Korea – name: 1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea |
Author_xml | – sequence: 1 givenname: Sun Bean surname: Kim fullname: Kim, Sun Bean organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 2 givenname: Kyoung Hwa surname: Lee fullname: Lee, Kyoung Hwa organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 3 givenname: Ji Un surname: Lee fullname: Lee, Ji Un organization: Department of Internal Medicine, Infectious Diseases, Hongik Hospital, Seoul, Korea – sequence: 4 givenname: Hea Won surname: Ann fullname: Ann, Hea Won organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 5 givenname: Jin Young surname: Ahn fullname: Ahn, Jin Young organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 6 givenname: Yong Duk surname: Jeon fullname: Jeon, Yong Duk organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 7 givenname: Jung Ho surname: Kim fullname: Kim, Jung Ho organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 8 givenname: Nam Su surname: Ku fullname: Ku, Nam Su organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 9 givenname: Sang Hoon surname: Han fullname: Han, Sang Hoon organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 10 givenname: Jun Yong surname: Choi fullname: Choi, Jun Yong organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 11 givenname: Young Goo surname: Song fullname: Song, Young Goo organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea – sequence: 12 givenname: June Myung surname: Kim fullname: Kim, June Myung organization: Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28120568$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002196523$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9kk9vEzEQxS1URNPCB-CCfITDLv6z9novSFVpS6VURG0QR8vxjhs3m3WwNxG59pPjJKUCDkiW5jC_92bkeSfoqA89IPSWkpLzqvm4XT6UjNC6FKpkJa_JCzSiTS0LVvH6CI2IoLwQdSOP0UlKD4SwmhL2Ch0zRRkRUo3Q4zj093gC_RDNT99jjk3CBk8itN4OfgP4xsQFRBwcvglxMJ0ftjiDd7CBCLmsBm_xxAw-eyT8fR7wLVjIyhbfra2FlNy6wxcmdlt8FUxXfPYR7JDb0zlEs9q-Ri-d6RK8eaqn6NvlxfT8SzH-enV9fjYubMX5UFSy4sCYaoTj0EjFZrSyvOFOciFIY5RoedsI6RQFJp1zppmBsjNTE9VKRvkp-nDw7aPTC-t1MH5f74NeRH12O73WlDPFlczspwO7Ws-W0Nr9_3R6Ff3SxO1e-Xen9_Pss9GCNSRfJBu8fzKI4cca0qCXPlnoOtNDWCdNldw_KjL67s9Zz0N-HykD9ADYGFKK4J4RSvQuCDoHQe-CoIXSTOcgZE39j8b6IR8p7Nb13X-UvwBFobmD |
CitedBy_id | crossref_primary_10_1016_j_jinf_2020_01_010 crossref_primary_10_1186_s12879_019_4618_7 crossref_primary_10_1186_s13054_022_04032_x crossref_primary_10_1016_j_jcrc_2018_06_004 crossref_primary_10_18632_oncotarget_23701 crossref_primary_10_3947_ic_2020_52_1_1 crossref_primary_10_4103_njcp_njcp_615_23 crossref_primary_10_3389_fimmu_2019_00794 crossref_primary_10_1016_j_jinf_2017_10_016 crossref_primary_10_3390_biomedicines9030311 crossref_primary_10_3389_fimmu_2019_00823 crossref_primary_10_1016_j_jinf_2018_04_014 crossref_primary_10_3389_fmed_2024_1398024 crossref_primary_10_1371_journal_pone_0243849 crossref_primary_10_1080_17460441_2021_1851186 |
Cites_doi | 10.1097/01.CCM.0000298158.12101.41 10.1086/377200 10.1016/j.hrtlng.2012.11.005 10.3349/ymj.2016.57.1.111 10.1016/j.jinf.2011.08.004 10.1007/s00134-003-1662-x 10.1182/blood.V87.5.1862.1862 10.1111/j.1440-1843.2011.02018.x 10.1001/jama.2009.1754 10.1056/NEJMoa1211161 10.1016/j.jinf.2009.04.004 10.1097/00003246-200107000-00017 10.1371/journal.pone.0073119 10.1155/2013/165974 10.1186/cc13145 10.3324/haematol.2011.044925 10.1097/CCM.0b013e3181809aaf 10.1097/01.CCM.0000117317.18092.E4 10.1371/journal.pone.0017653 10.1586/eri.13.9 10.1016/0021-9681(87)90171-8 10.1007/BF01709751 10.1002/hep.25551 10.1186/1471-2334-11-299 10.1159/000339789 10.1097/00003246-198510000-00009 10.1111/j.1600-065X.2008.00719.x 10.1155/2012/920517 10.1007/s00134-012-2769-8 10.1371/journal.pone.0053661 10.1080/00365519709168308 10.1378/chest.115.3.829 10.1097/SHK.0b013e31817fd543 10.1097/SHK.0b013e3182454acf 10.1056/NEJMoa010307 10.1016/j.ajem.2012.10.017 10.1515/cclm-2012-0459 10.1016/S0021-9258(18)41653-5 10.1007/s00134-010-1752-5 |
ContentType | Journal Article |
Copyright | Copyright: Yonsei University College of Medicine 2017 2017 |
Copyright_xml | – notice: Copyright: Yonsei University College of Medicine 2017 2017 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ACYCR |
DOI | 10.3349/ymj.2017.58.2.370 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1976-2437 |
EndPage | 379 |
ExternalDocumentID | oai_kci_go_kr_ARTI_1328386 PMC5290017 28120568 10_3349_ymj_2017_58_2_370 |
Genre | Journal Article |
GroupedDBID | --- .55 .GJ 123 29R 2WC 36B 5-W 53G 5RE 8JR 8XY 9ZL AAYXX ACYCR ADBBV ADRAZ AEGXH AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION CS3 DIK DU5 E3Z EBD EF. EMB EMOBN F5P GROUPED_DOAJ GX1 HYE KQ8 L7B M48 MK0 O5R O5S OK1 OVT P2P PGMZT RNS RPM SV3 TR2 X7M XSB ZGI ZXP CGR CUY CVF ECM EIF NPM 7X8 5PM M~E |
ID | FETCH-LOGICAL-c433t-4643e22895f3e9682b14c393f635509a85d3d956f81e26fffa9be8cba708d6213 |
IEDL.DBID | M48 |
ISSN | 0513-5796 1976-2437 |
IngestDate | Tue Nov 21 21:40:30 EST 2023 Thu Aug 21 18:31:11 EDT 2025 Thu Jul 10 18:18:55 EDT 2025 Thu Apr 03 07:02:00 EDT 2025 Thu Apr 24 23:06:44 EDT 2025 Tue Jul 01 04:03:06 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | mortality predictive biomarker Pentraxin 3 severe sepsis early-goal directed therapy |
Language | English |
License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c433t-4643e22895f3e9682b14c393f635509a85d3d956f81e26fffa9be8cba708d6213 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-000409.2017.58.2.012 http://ymj.kr/DOIx.php?id=10.3349/ymj.2017.58.2.370 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3349/ymj.2017.58.2.370 |
PMID | 28120568 |
PQID | 1861861815 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_1328386 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5290017 proquest_miscellaneous_1861861815 pubmed_primary_28120568 crossref_primary_10_3349_ymj_2017_58_2_370 crossref_citationtrail_10_3349_ymj_2017_58_2_370 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-03-01 |
PublicationDateYYYYMMDD | 2017-03-01 |
PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Korea (South) |
PublicationPlace_xml | – name: Korea (South) |
PublicationTitle | Yonsei medical journal |
PublicationTitleAlternate | Yonsei Med J |
PublicationYear | 2017 |
Publisher | Yonsei University College of Medicine 연세대학교의과대학 |
Publisher_xml | – name: Yonsei University College of Medicine – name: 연세대학교의과대학 |
References | Park (10.3349/ymj.2017.58.2.370_ref37) 2011; 11 Rivers (10.3349/ymj.2017.58.2.370_ref17) 2001; 345 Charlson (10.3349/ymj.2017.58.2.370_ref18) 1987; 40 Kang (10.3349/ymj.2017.58.2.370_ref21) 2003; 37 Cunha (10.3349/ymj.2017.58.2.370_ref40) 2014; 370 Vincent (10.3349/ymj.2017.58.2.370_ref35) 2013; 11 Vänskä (10.3349/ymj.2017.58.2.370_ref28) 2011; 96 Vincent (10.3349/ymj.2017.58.2.370_ref19) 1996; 22 Huttunen (10.3349/ymj.2017.58.2.370_ref31) 2011; 6 Breviario (10.3349/ymj.2017.58.2.370_ref3) 1992; 267 Kunes (10.3349/ymj.2017.58.2.370_ref14) 2012; 2012 Nahm (10.3349/ymj.2017.58.2.370_ref24) 2008; 38 Knaus (10.3349/ymj.2017.58.2.370_ref20) 1985; 13 Dellinger (10.3349/ymj.2017.58.2.370_ref26) 2004; 32 Kao (10.3349/ymj.2017.58.2.370_ref34) 2013; 51 Hasday (10.3349/ymj.2017.58.2.370_ref2) 1999; 115 Vincent (10.3349/ymj.2017.58.2.370_ref5) 2009; 302 Lee (10.3349/ymj.2017.58.2.370_ref7) 2016; 57 Boyd (10.3349/ymj.2017.58.2.370_ref27) 1997; 227 Mauri (10.3349/ymj.2017.58.2.370_ref10) 2008; 36 Lee (10.3349/ymj.2017.58.2.370_ref23) 2012; 55 Muller (10.3349/ymj.2017.58.2.370_ref11) 2001; 29 Dellinger (10.3349/ymj.2017.58.2.370_ref6) 2013; 39 Huttunen (10.3349/ymj.2017.58.2.370_ref9) 2011; 63 Mauri (10.3349/ymj.2017.58.2.370_ref29) 2010; 36 Uusitalo-Seppälä (10.3349/ymj.2017.58.2.370_ref12) 2013; 8 Huh (10.3349/ymj.2017.58.2.370_ref25) 2011; 16 Khwaja (10.3349/ymj.2017.58.2.370_ref22) 2012; 120 Seok (10.3349/ymj.2017.58.2.370_ref36) 2012; 37 Sprong (10.3349/ymj.2017.58.2.370_ref33) 2009; 31 Bottazzi (10.3349/ymj.2017.58.2.370_ref1) 2009; 227 Introna (10.3349/ymj.2017.58.2.370_ref4) 1996; 87 Lin (10.3349/ymj.2017.58.2.370_ref30) 2013; 42 Dellinger (10.3349/ymj.2017.58.2.370_ref15) 2008; 36 Levy (10.3349/ymj.2017.58.2.370_ref16) 2003; 29 Schulte (10.3349/ymj.2017.58.2.370_ref8) 2013; 2013 Wagenaar (10.3349/ymj.2017.58.2.370_ref32) 2009; 58 Bastrup-Birk (10.3349/ymj.2017.58.2.370_ref13) 2013; 8 Kim (10.3349/ymj.2017.58.2.370_ref38) 2013; 17 Jo (10.3349/ymj.2017.58.2.370_ref39) 2013; 31 26632390 - Yonsei Med J. 2016 Jan;57(1):111-7 12664219 - Intensive Care Med. 2003 Apr;29(4):530-8 20119647 - Intensive Care Med. 2010 Apr;36(4):621-9 19443038 - J Infect. 2009 Jun;58(6):425-32 11794169 - N Engl J Med. 2001 Nov 8;345(19):1368-77 8844239 - Intensive Care Med. 1996 Jul;22(7):707-10 19952319 - JAMA. 2009 Dec 2;302(21):2323-9 22258230 - Shock. 2012 Mar;37(3):242-6 23380094 - Am J Emerg Med. 2013 Mar;31(3):545-8 9127468 - Scand J Clin Lab Invest Suppl. 1997;227:46-63 3928249 - Crit Care Med. 1985 Oct;13(10):818-29 18158437 - Crit Care Med. 2008 Jan;36(1):296-327 18596636 - Crit Care Med. 2008 Aug;36(8):2302-8 12955633 - Clin Infect Dis. 2003 Sep 15;37(6):745-51 22890468 - Nephron Clin Pract. 2012;120(4):c179-84 1429570 - J Biol Chem. 1992 Nov 5;267(31):22190-7 23458767 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):265-75 24039869 - PLoS One. 2013 Sep 09;8(9):e73119 23341967 - PLoS One. 2013;8(1):e53661 23361625 - Intensive Care Med. 2013 Feb;39(2):165-228 24321201 - Crit Care. 2013 Dec 09;17(6):R282 22577258 - Mediators Inflamm. 2012;2012:920517 11445697 - Crit Care Med. 2001 Jul;29(7):1404-7 15090974 - Crit Care Med. 2004 Mar;32(3):858-73 23273657 - Heart Lung. 2013 Mar-Apr;42(2):139-45 21423699 - PLoS One. 2011 Mar 10;6(3):e17653 3558716 - J Chronic Dis. 1987;40(5):373-83 21840338 - J Infect. 2011 Dec;63(6):407-19 21880642 - Haematologica. 2011 Sep;96(9):1385-9 10084499 - Chest. 1999 Mar;115(3):829-35 18715852 - Ann Clin Lab Sci. 2008 Summer;38(3):241-6 22040292 - BMC Infect Dis. 2011 Nov 01;11:299 8634434 - Blood. 1996 Mar 1;87(5):1862-72 22213561 - Hepatology. 2012 Mar;55(3):965-7 24476432 - N Engl J Med. 2014 Jan 30;370(5):421-32 18650775 - Shock. 2009 Jan;31(1):28-32 19120471 - Immunol Rev. 2009 Jan;227(1):9-18 21726354 - Respirology. 2011 Oct;16(7):1088-95 23152412 - Clin Chem Lab Med. 2013 Apr;51(4):907-13 23853427 - Mediators Inflamm. 2013;2013:165974 |
References_xml | – volume: 36 start-page: 296 year: 2008 ident: 10.3349/ymj.2017.58.2.370_ref15 publication-title: Crit Care Med doi: 10.1097/01.CCM.0000298158.12101.41 – volume: 37 start-page: 745 year: 2003 ident: 10.3349/ymj.2017.58.2.370_ref21 publication-title: Clin Infect Dis doi: 10.1086/377200 – volume: 42 start-page: 139 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref30 publication-title: Heart Lung doi: 10.1016/j.hrtlng.2012.11.005 – volume: 57 start-page: 111 year: 2016 ident: 10.3349/ymj.2017.58.2.370_ref7 publication-title: Yonsei Med J doi: 10.3349/ymj.2016.57.1.111 – volume: 63 start-page: 407 year: 2011 ident: 10.3349/ymj.2017.58.2.370_ref9 publication-title: J Infect doi: 10.1016/j.jinf.2011.08.004 – volume: 29 start-page: 530 year: 2003 ident: 10.3349/ymj.2017.58.2.370_ref16 publication-title: Intensive Care Med doi: 10.1007/s00134-003-1662-x – volume: 87 start-page: 1862 year: 1996 ident: 10.3349/ymj.2017.58.2.370_ref4 publication-title: Blood doi: 10.1182/blood.V87.5.1862.1862 – volume: 16 start-page: 1088 year: 2011 ident: 10.3349/ymj.2017.58.2.370_ref25 publication-title: Respirology doi: 10.1111/j.1440-1843.2011.02018.x – volume: 302 start-page: 2323 year: 2009 ident: 10.3349/ymj.2017.58.2.370_ref5 publication-title: JAMA doi: 10.1001/jama.2009.1754 – volume: 370 start-page: 421 year: 2014 ident: 10.3349/ymj.2017.58.2.370_ref40 publication-title: N Engl J Med doi: 10.1056/NEJMoa1211161 – volume: 58 start-page: 425 year: 2009 ident: 10.3349/ymj.2017.58.2.370_ref32 publication-title: J Infect doi: 10.1016/j.jinf.2009.04.004 – volume: 29 start-page: 1404 year: 2001 ident: 10.3349/ymj.2017.58.2.370_ref11 publication-title: Crit Care Med doi: 10.1097/00003246-200107000-00017 – volume: 8 start-page: e73119 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref13 publication-title: PLoS One doi: 10.1371/journal.pone.0073119 – volume: 2013 start-page: 165974 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref8 publication-title: Mediators Inflamm doi: 10.1155/2013/165974 – volume: 17 start-page: R282 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref38 publication-title: Crit Care doi: 10.1186/cc13145 – volume: 96 start-page: 1385 year: 2011 ident: 10.3349/ymj.2017.58.2.370_ref28 publication-title: Haematologica doi: 10.3324/haematol.2011.044925 – volume: 36 start-page: 2302 year: 2008 ident: 10.3349/ymj.2017.58.2.370_ref10 publication-title: Crit Care Med doi: 10.1097/CCM.0b013e3181809aaf – volume: 32 start-page: 858 year: 2004 ident: 10.3349/ymj.2017.58.2.370_ref26 publication-title: Crit Care Med doi: 10.1097/01.CCM.0000117317.18092.E4 – volume: 6 start-page: e17653 year: 2011 ident: 10.3349/ymj.2017.58.2.370_ref31 publication-title: PLoS One doi: 10.1371/journal.pone.0017653 – volume: 11 start-page: 265 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref35 publication-title: Expert Rev Anti Infect Ther doi: 10.1586/eri.13.9 – volume: 40 start-page: 373 year: 1987 ident: 10.3349/ymj.2017.58.2.370_ref18 publication-title: J Chronic Dis doi: 10.1016/0021-9681(87)90171-8 – volume: 22 start-page: 707 year: 1996 ident: 10.3349/ymj.2017.58.2.370_ref19 publication-title: Intensive Care Med doi: 10.1007/BF01709751 – volume: 55 start-page: 965 year: 2012 ident: 10.3349/ymj.2017.58.2.370_ref23 publication-title: Hepatology doi: 10.1002/hep.25551 – volume: 11 start-page: 299 year: 2011 ident: 10.3349/ymj.2017.58.2.370_ref37 publication-title: BMC Infect Dis doi: 10.1186/1471-2334-11-299 – volume: 120 start-page: c179 year: 2012 ident: 10.3349/ymj.2017.58.2.370_ref22 publication-title: Nephron Clin Pract doi: 10.1159/000339789 – volume: 13 start-page: 818 year: 1985 ident: 10.3349/ymj.2017.58.2.370_ref20 publication-title: Crit Care Med doi: 10.1097/00003246-198510000-00009 – volume: 227 start-page: 9 year: 2009 ident: 10.3349/ymj.2017.58.2.370_ref1 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2008.00719.x – volume: 2012 start-page: 920517 year: 2012 ident: 10.3349/ymj.2017.58.2.370_ref14 publication-title: Mediators Inflamm doi: 10.1155/2012/920517 – volume: 39 start-page: 165 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref6 publication-title: Intensive Care Med doi: 10.1007/s00134-012-2769-8 – volume: 8 start-page: e53661 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref12 publication-title: PLoS One doi: 10.1371/journal.pone.0053661 – volume: 227 start-page: 46 year: 1997 ident: 10.3349/ymj.2017.58.2.370_ref27 publication-title: Scand J Clin Lab Invest Suppl doi: 10.1080/00365519709168308 – volume: 115 start-page: 829 year: 1999 ident: 10.3349/ymj.2017.58.2.370_ref2 publication-title: Chest doi: 10.1378/chest.115.3.829 – volume: 31 start-page: 28 year: 2009 ident: 10.3349/ymj.2017.58.2.370_ref33 publication-title: Shock doi: 10.1097/SHK.0b013e31817fd543 – volume: 37 start-page: 242 year: 2012 ident: 10.3349/ymj.2017.58.2.370_ref36 publication-title: Shock doi: 10.1097/SHK.0b013e3182454acf – volume: 345 start-page: 1368 year: 2001 ident: 10.3349/ymj.2017.58.2.370_ref17 publication-title: N Engl J Med doi: 10.1056/NEJMoa010307 – volume: 31 start-page: 545 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref39 publication-title: Am J Emerg Med doi: 10.1016/j.ajem.2012.10.017 – volume: 38 start-page: 241 year: 2008 ident: 10.3349/ymj.2017.58.2.370_ref24 publication-title: Ann Clin Lab Sci – volume: 51 start-page: 907 year: 2013 ident: 10.3349/ymj.2017.58.2.370_ref34 publication-title: Clin Chem Lab Med doi: 10.1515/cclm-2012-0459 – volume: 267 start-page: 22190 year: 1992 ident: 10.3349/ymj.2017.58.2.370_ref3 publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)41653-5 – volume: 36 start-page: 621 year: 2010 ident: 10.3349/ymj.2017.58.2.370_ref29 publication-title: Intensive Care Med doi: 10.1007/s00134-010-1752-5 – reference: 24039869 - PLoS One. 2013 Sep 09;8(9):e73119 – reference: 23273657 - Heart Lung. 2013 Mar-Apr;42(2):139-45 – reference: 24321201 - Crit Care. 2013 Dec 09;17(6):R282 – reference: 11794169 - N Engl J Med. 2001 Nov 8;345(19):1368-77 – reference: 24476432 - N Engl J Med. 2014 Jan 30;370(5):421-32 – reference: 12955633 - Clin Infect Dis. 2003 Sep 15;37(6):745-51 – reference: 23853427 - Mediators Inflamm. 2013;2013:165974 – reference: 19120471 - Immunol Rev. 2009 Jan;227(1):9-18 – reference: 8844239 - Intensive Care Med. 1996 Jul;22(7):707-10 – reference: 10084499 - Chest. 1999 Mar;115(3):829-35 – reference: 23341967 - PLoS One. 2013;8(1):e53661 – reference: 20119647 - Intensive Care Med. 2010 Apr;36(4):621-9 – reference: 18650775 - Shock. 2009 Jan;31(1):28-32 – reference: 8634434 - Blood. 1996 Mar 1;87(5):1862-72 – reference: 19952319 - JAMA. 2009 Dec 2;302(21):2323-9 – reference: 1429570 - J Biol Chem. 1992 Nov 5;267(31):22190-7 – reference: 22040292 - BMC Infect Dis. 2011 Nov 01;11:299 – reference: 26632390 - Yonsei Med J. 2016 Jan;57(1):111-7 – reference: 18715852 - Ann Clin Lab Sci. 2008 Summer;38(3):241-6 – reference: 21840338 - J Infect. 2011 Dec;63(6):407-19 – reference: 19443038 - J Infect. 2009 Jun;58(6):425-32 – reference: 22213561 - Hepatology. 2012 Mar;55(3):965-7 – reference: 23361625 - Intensive Care Med. 2013 Feb;39(2):165-228 – reference: 15090974 - Crit Care Med. 2004 Mar;32(3):858-73 – reference: 21423699 - PLoS One. 2011 Mar 10;6(3):e17653 – reference: 9127468 - Scand J Clin Lab Invest Suppl. 1997;227:46-63 – reference: 23380094 - Am J Emerg Med. 2013 Mar;31(3):545-8 – reference: 12664219 - Intensive Care Med. 2003 Apr;29(4):530-8 – reference: 21880642 - Haematologica. 2011 Sep;96(9):1385-9 – reference: 3928249 - Crit Care Med. 1985 Oct;13(10):818-29 – reference: 22577258 - Mediators Inflamm. 2012;2012:920517 – reference: 22258230 - Shock. 2012 Mar;37(3):242-6 – reference: 22890468 - Nephron Clin Pract. 2012;120(4):c179-84 – reference: 18158437 - Crit Care Med. 2008 Jan;36(1):296-327 – reference: 11445697 - Crit Care Med. 2001 Jul;29(7):1404-7 – reference: 23152412 - Clin Chem Lab Med. 2013 Apr;51(4):907-13 – reference: 18596636 - Crit Care Med. 2008 Aug;36(8):2302-8 – reference: 23458767 - Expert Rev Anti Infect Ther. 2013 Mar;11(3):265-75 – reference: 21726354 - Respirology. 2011 Oct;16(7):1088-95 – reference: 3558716 - J Chronic Dis. 1987;40(5):373-83 |
SSID | ssj0027102 |
Score | 2.2146084 |
Snippet | Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limited data on biomarkers including PTX3... Purpose: Pentraxin 3 (PTX3) has been suggested to be a prognostic marker of mortality in severe sepsis. Currently, there are limiteddata on biomarkers... |
SourceID | nrf pubmedcentral proquest pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 370 |
SubjectTerms | Aged APACHE Biomarkers - blood C-Reactive Protein - analysis C-Reactive Protein - metabolism Calcitonin - blood Cause of Death Female Humans Leukocyte Count Male Middle Aged Neutrophils Organ Dysfunction Scores Original Prognosis Proportional Hazards Models Prospective Studies Reference Standards ROC Curve Sensitivity and Specificity Sepsis - blood Sepsis - mortality Serum Amyloid P-Component - analysis Time Factors 의학일반 |
Title | Long Pentraxin 3 as a Predictive Marker of Mortality in Severe Septic Patients Who Received Successful Early Goal-Directed Therapy |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28120568 https://www.proquest.com/docview/1861861815 https://pubmed.ncbi.nlm.nih.gov/PMC5290017 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002196523 |
Volume | 58 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Yonsei Medical Journal, 2017, 58(2), , pp.370-379 |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1976-2437 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0027102 issn: 0513-5796 databaseCode: KQ8 dateStart: 20050101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1976-2437 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0027102 issn: 0513-5796 databaseCode: DOA dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1976-2437 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0027102 issn: 0513-5796 databaseCode: DIK dateStart: 19600101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1976-2437 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0027102 issn: 0513-5796 databaseCode: GX1 dateStart: 19600101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 1976-2437 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0027102 issn: 0513-5796 databaseCode: 5-W dateStart: 19600101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central Free customDbUrl: eissn: 1976-2437 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0027102 issn: 0513-5796 databaseCode: RPM dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1976-2437 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0027102 issn: 0513-5796 databaseCode: M48 dateStart: 20050201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELe2ISFeEN9kQGUQT0guiT8S5wEhhBgDUVRpq7Y3K3HsrawkI22l7ZW_nDsnLRRVCCmSH2znw3c-_37x-Y6Ql6VXsatkyaROBQMrKZlWuWPW8hIqeJZZPDs8-poeTuTnU3W6Q1bprfoBnG-ldphPatLOhlc_rt_ChH-DjFPI_PX192_oo5UNlR7yociAwd-AhYmjko-k_s2_kuCCCGooGB7B7DY5t99iY5narVu_DYH-7Uj5x8p0cIfc7iElfdfpwF2y4-p75Oao3zS_T35-aeozOg6dr6Y1FbSY04KOW2yB1o7igR3X0sbTURgIQOYUGh450HMHBZgVS8ddBNY5PTlvKKBNBz0rerQMGRf9ckZDrGT6sSlmrDOkUH3cBS14QCYHH47fH7I-9QKzUogFkwBUHAcyprxweap5mUgrcuERn8R5oVUlKqBWXieOp977Ii-dtmWRxbpKeSIekr26qd1jQm2WhcBiaVlV0gNCkKVQEs1qHPusiiMSr0ba2D4uOabHmBngJygcA8IxKByjtOEGhBORV-sul11Qjn81fgHiMxd2ajCUNpZnjbloDRCGTwbIuBY6jcjzlXQNzC_cNClq1yznJtFpuBIVkUedtNfP5ICOAEDqiGQberBugA_crKmn5yGGt-I5AoT9_3m5J-QWflHn-faU7C3apXsGUGhRDsiuYieD8CNhEJT9FxI7CBM |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+Pentraxin+3+as+a+Predictive+Marker+of+Mortality+in+Severe+Septic+Patients+Who+Received+Successful+Early+Goal-Directed+Therapy&rft.jtitle=Yonsei+medical+journal&rft.au=%EA%B9%80%EC%84%A0%EB%B9%88&rft.au=%ED%95%9C%EC%83%81%ED%9B%88&rft.au=%EC%9D%B4%EA%B2%BD%ED%99%94&rft.au=%EC%9D%B4%EC%A7%80%EC%96%B8&rft.date=2017-03-01&rft.pub=%EC%97%B0%EC%84%B8%EB%8C%80%ED%95%99%EA%B5%90%EC%9D%98%EA%B3%BC%EB%8C%80%ED%95%99&rft.issn=0513-5796&rft.eissn=1976-2437&rft.spage=370&rft.epage=379&rft_id=info:doi/10.3349%2Fymj.2017.58.2.370&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_1328386 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0513-5796&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0513-5796&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0513-5796&client=summon |